{
  "id": 16807105,
  "title": "Fenebrutinib May Curb Chronic Active Lesions in Multiple Sclerosis",
  "url": "https://urgent.news/2026/10/27/fenebrutinib-may-curb-chronic-active-lesions-in-multiple-sclerosis",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-27T21:21:43.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/ectrims/123611"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- The investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib may curb chronic active lesions in multiple sclerosis (MS), data from phase III trials suggested. Two MRI biomarkers in MS are slowly expanding lesions...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}